← Leaderboards
Richard Slayden
Colorado State University
$2,918,793
Attributed
$2,918,793
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2017–24$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,918,793 · 4
By mechanism
N01$2,918,793 · 4
Top collaborators
No co-investigators on record.
Most similar at Colorado State University
Same institution · by research overlap
- Raymond Paul Goodrich$4,057,902
- Michael F Antolin$2,948,118
- Brian Howard Kvitko$89,503
- Colleen T Webb$7,667,081
- Ken Gage$320,250
Others in their field
Other Emerging Leaders on “Contracts”
- Leonard Freedman · Leidos Biomedical Research, Inc.$811,365,654
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lynn Briscoe · Leidos Biomedical Research, Inc.$236,279,699
- Leonard Freedmand · Leidos Biomedical Research, Inc.$165,274,216
- Kimberly Smith · Ppd Development Lp$116,584,264
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$95,500,810
Research focus
ContractsTherapeutic DevelopmentIn Vitro TestingMaintenanceAnti-Bacterial AgentsAntifungal AgentsAdvanced DevelopmentPathogenIn VitroScreeningBiodefenseEmerging Communicable DiseasesBacteriaFungusCombatMycotoxinsToxinBasic ScienceAntimicrobial ResistanceAnimal ModelBacillus AnthracisExtramural ActivitiesAcquired Immunodeficiency SyndromeDrug Combinations
Grant awards (11)
Testing of Drug Combinations For Mycobacterium tuberculosis (MTB) in Mice$207,029
N01 · FY2024 · AI · contact PI
Task A05: Collection of Metadata from In Vivo Studies Performed Under Previous IDIQ Contract Mechanisms$56,795
N01 · FY2024 · AI · contact PI
Testing of Drug Combinations For Mycobacterium tuberculosis (MTB) in Mice$1,250,319
N01 · FY2022 · AI · contact PI
Task A03: In Vitro Screening for Antibacterial Activity Against Biodefense and Emerging Infectious Disease Pathogens$53,311
N01 · FY2020 · AI · contact PI
Task A07: Anti-mycobacterial Target or Mechanism Identification contract (AToMIc)$52,584
N01 · FY2020 · AI · contact PI
Task A07: Anti-mycobacterial Target or Mechanism Identification contract (AToMIc)$880,685
N01 · FY2019 · AI · contact PI
Task A03: In Vitro Screening for Antibacterial Activity Against Biodefense and Emerging Infectious Disease Pathogens$157,433
N01 · FY2019 · AI · contact PI
Task A34: In vitro screening for antibacterial activity against biodefense and emerging infectious disease pathogens$16,582
N01 · FY2019 · AI · contact PI
In Vitro Assessment for Antimicrobial Activity Support (Task Area A)$2,500
N01 · FY2019 · AI · contact PI
Task A34: In vitro screening for antibacterial activity against biodefense and emerging infectious disease pathogens$159,933
N01 · FY2018 · AI · contact PI
TASK A30: In vitro screening for antibacterial activity against biodefense and emerging infectious disease pathogens$81,622
N01 · FY2017 · AI · contact PI